Loading…
Based on limited metadata, this warning letter was issued to MannKind Corporation, a pharmaceutical company, on October 5, 2018, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The FDA's regulatory scope covers drug manufacturing, marketing, or compliance practices, though the specific issuing office and detailed violation categories are not specified in this metadata summary.